Simon Rothwell

Eisai is a global research and development-based pharmaceutical company specialising in oncology and neurology products. In my current role, I lead Eisai's Global Market Access team in our goal to optimize and sustain patient access and reimbursement for all Eisai's branded treatment portfolio and pipeline. We do this by developing and driving sound global strategies for all aspects of reimbursement, market access, adoption and pricing; providing best practice support to our country market access affiliates and external partners in their reimbursement activities; working cross-functionally to ensure that reimbursement requirements are considered throughout clinical development and that the wider business is informed of market access opportunities, risks, plans and progress. I also lead development and refinement of global payer-value materials, including value dossiers, treatable & eligible patient number models, cost-effectiveness and budget impact models. Throughout my time at Eisai, I have worked on over 100 reimbursement / HTA submissions, made across 42 countries, and across both oncology and neurology disease areas, including Alzheimer's disease (AD). Nearly half of these submissions were for a dual-branded oncology combination therapy. In addition to my global role, I am a member of Eisai's EMEA Core AD team, set up to lead activities across the EMEA region, supporting preparations for the launch of a disease-modifying therapy for AD.

In my role as Associate Director within Eisai's Global Market Access team, I was responsible for driving overall global strategy for all aspects of reimbursement, market access, adoption and pricing across Eisai's oncology and AD portfolio, helping to secure optimal access and reimbursement by supporting country affiliates and partners in the adaptation of global materials, preparing local submissions and pricing negotiations.

Responsibilities as above.

PAREXEL Access Consulting is a global healthcare consultancy company specialising in pricing and market access, HEOR, and real-world evidence analytics. During my time as a Consultant within the PAREXEL Access Consulting Pricing and Market Access team I was responsible for the management and delivery of value communication and primary research projects, including disease and treatment landscape assessments, HTA-based projects, value dossiers, value story development and testing, and the development of real-world observational studies, primarily for neurology and oncology healthcare products. I continued to play an active role in thought leadership activities.

During my time as a Senior Associate within the PAREXEL Access Consulting Pricing and Market Access team, I was primarily responsible for the delivery of, and to a lesser extent management of, value communication and primary research-based projects, particularly for neurology and oncology healthcare products. I also played an active role in thought leadership activities, the results of which were presented at the 2018 European conference of the International Society for Pharmacoeconomic and Outcomes Research (ISPOR).

Evidera is a global healthcare consultancy company specialising in market access, HEOR, and real-world evidence analytics. During my time as a Market Access Writer II within the Market Access Communications department of Evidera, I was involved in the delivery of, and to a lesser extent the management of, a number of projects, producing: global value dossiers, slide decks and advisory board reports, along with a number of other market-access related deliverables. My projects encompassed multiple disease and treatment areas including Parkinson’s Disease, oncology, intensive care unit therapeutics and advanced therapy medicinal products (ATMPs). In addition to my client based work, I also managed an international thought leadership payer research project, the findings from which were presented at the 20th meeting of the International Society for Pharmacoeconomic and Outcomes Research (ISPOR).

During my time as a Market Access Writer I within the Market Access Communications department of Evidera, I was involved in the delivery of a number of projects, producing: global value dossiers, slide decks and advisory board reports, along with a number of other market-access related deliverables across a range of therapeutic areas.

My responsibilities included: • Developing and managing biophysical and neuropharmacological research projects • Analysing, presenting and communicating scientific evidence • Producing and editing academic manuscripts for publication • Developing strategies towards future avenues of research • Small group teaching of university students. My work at UCL resulted in three publications in international peer-reviewed journals.

My responsibilities included: • Data collection • Statistical analysis of experimental data • Presenting figures to specification and developing an academic manuscript for publication within an internationally respected scientific journal. I presented my work at a national meeting of the UK Purine club, held at the University of East Anglia in 2013.

I provided technical support to multiple research groups, maintaining up to date records of stocks and purchasing, and ensuring each lab was compliant with the appropriate health and safety regulations.

CASE PhD studentship in partnership with AstraZeneca. My PhD project focused on the molecular modus operandi of the ATP-gated P2X receptors. My work was published in three international peer-reviewed journals. My responsibilities included: • Managing multiple independent and collaborative research projects • Data collection • Statisical analysis • Written and oral communication of experimental findings • Developing new avenues of scientific research • Providing guidance and expertise on the academic and technical aspects of P2X receptor research to collaborators.